Checkpoint Inhibitors in Squamous Non-Small Cell
Lung Cancer (NSCLC)
Volume 2 - Issue 3
Bakulesh Khamar*
-
Author Information
Open or Close
- R&D Department, Cadila Pharmaceuticals Limited, Ahmedabad, India
*Corresponding author:
Bakulesh Khamar, Cadila Pharmaceuticals Limited, Cadila Corporate Campus Sarkhej-Dholka Road, Bhat,
Ahmedabad, Gujarat, India
Received: August 08, 2018; Published: August 14, 2018
DOI: 10.32474/OAJOM.2018.02.000140
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a
monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second line or consolidation
therapy. As a first line, Pembrolizumab improves outcome (PFS) as a monotherapy in patients with PD-L1 expression of ≥ 50% (HR;
0.35). When used with chemotherapy, it improves PFS (HR; 0.56) irrespective of PD-L1 expression level. Nivolumab also improves
PFS (HR; 0.62), when used as a second line for those progressing with chemotherapy. Durvalumab improves PFS (HR; 0.68) when
used following chemo-radio therapy as a consolidation therapy.
Keywords: Checkpoint Inhibitors; Pembrolizumab; Nivolumab; Atezolizumab; Durvalumab; PD-L1; Squamous NSCLC; Progression
Free Survival; Overall Survival
Abstract|
Introduction|
Checkpoint inhibitors as a Consolidation therapy|
Checkpoint Inhibitors as a Second Line Therapy|
Checkpoint Inhibitors as a Third Line Therapy|
Checkpoint Inhibitors and Management of
Squamous NSCLC- Recent Advances|
Conclusion|
References|